Brain Penetration of the ROS1/ALK Inhibitor Lorlatinib Confirmed by PET
{{output}}
The Massachusetts General Hospital Radiochemistry Program, in collaboration with Pfizer, has developed unique 11C and 18F-labeling strategies to synthesize isotopologs of lorlatinib (PF-06463922) which is undergoing phase III clinical trial investigations for ... ...
